Print

IGPA Files Recommendations for USTR 2015 Special 301 Review

February 13, 2015 – IGPA has filed its inaugural submission with the Office of the United States Trade Representative (USTR) as part of USTR`s 2015 Special 301 Review. The IGPA submission identifies a number of trade barriers and impediments for the generic pharmaceutical and biosimilar medicines industries.

Read More

 

 

 

 

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

Rue d'Arlon, 50
B-1000 Brussels, Belgium

Telephone: +32 (0)2 736 84 11
Fax: +32 (0)2 736 74 38
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site